Inhibitex Reports Results of Interim Analysis of Phase II Clinical Trial of
FV-100
Trial Continues as Planned after Scheduled DSMB Safety Review and Interim
Analysis
ATLANTA, Apr 12, 2010 (BUSINESS WIRE) -- Inhibitex, Inc. (INHX) today announced
that the independent Data Safety Monitoring Board (DSMB) responsible for
reviewing safety data from the Company's ongoing Phase II clinical trial of
FV-100 met, as scheduled, after the Company had provided it with 30-day follow-up
data on the first half of the patients that the Company plans to enroll in the
trial. In addition, an independent statistician conducted a prospectively
described interim analysis on the primary endpoint, which is the reduction in a
composite of the severity and duration of shingles-associated pain over the first
thirty (30) days of follow-up. Based upon the results of these reviews, the trial
will continue, as originally designed, without modification. The Company, which
remains blinded to the efficacy data, anticipates that top-line data from the
completed trial will be available in the fourth quarter of 2010.
The Phase II trial is a well-controlled, double-blind study comparing two arms of
FV-100, which the Company is developing for the treatment of shingles, to an
active control (valacyclovir). The Company plans to enroll and randomize
approximately 350 shingles patients, aged 50 years and older, equally to one of
three treatment arms: 200 mg FV-100 administered once daily; 400 mg FV-100
administered once daily; and 1,000 mg valacyclovir administered three times per
day. In addition to further evaluating its safety, the objectives of the trial
are to evaluate the potential therapeutic benefit of FV-100 in reducing the
severity and duration of shingles-associated pain, the incidence of post herpetic
neuralgia (PHN), and the time to lesion healing.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical
company focused on developing products to prevent and treat serious infectious
diseases. The Company's pipeline includes FV-100 and INX-189, a nucleotide
polymerase inhibitor in development for the treatment of chronic hepatitis C
infections. The Company has additional HCV nucleotide polymerase inhibitors in
preclinical development, and has also licensed the use of its proprietary
MSCRAMM(R) protein platform to Pfizer for the development of staphylococcal
vaccines.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 that involve substantial risks
and uncertainties. All statements, other than historical facts included in this
press release, including statements regarding the anticipated time to complete
and have top-line data available from its ongoing Phase II trial, and the
anticipated number of patients the Company plans to enroll in this trial, are
forward looking statements. These intentions, expectations, or results may not be
achieved in the future and various important factors and risks could cause actual
results or events to differ materially from the forward-looking statements that
the Company makes, including the risk of: either the Company, the FDA, an
investigational review board, or the DSMB suspending or terminating the clinical
development of FV-100 for safety concerns, manufacturing issues or lack of
efficacy; FV-100 not demonstrating sufficient efficacy in reducing the incidence
and severity of shingles-related symptoms, including acute pain and PHN, to be
clinically relevant or commercially viable; the clinical sites participating in
the FV-100 Phase II trial not being able to recruit a sufficient number of
shingles patients to complete the trial on a timely basis; and obtaining,
maintaining and protecting the intellectual property incorporated into and
supporting the commercial viability of the Company's product candidates. Further
information regarding these factors and risks can be found in the Company's
Annual Report on Form 10-K for the year ended December 31, 2009, as filed with
the Securities and Exchange Commission, or SEC, on March 26, 2010. Given these
uncertainties, you should not place undue reliance on these forward-looking
statements, which apply only as of the date of this press release.
There may be events in the future that the Company is unable to predict
accurately, or over which it has no control. The Company's business, financial
condition, results of operations and prospects may change. The Company may not
update these forward-looking statements, even though its situation may change in
the future, unless it has obligations under the Federal securities laws to update
and disclose material developments related to previously disclosed information.
The Company qualifies all of the information contained in this press release, and
particularly its forward-looking statements, by these cautionary statements.
Inhibitex(R) and MSCRAMM(R) are registered trademarks of Inhibitex, Inc.
SOURCE: Inhibitex, Inc.
Inhibitex, Inc.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
rplumb@inhibitex.com
or
The Trout Group
Lee Stern, 646-378-2922
lstern@troutgroup.com
Copyright Business Wire 2010
AI
